Literature DB >> 24177423

Apelin is a positive regulator of ACE2 in failing hearts.

Teruki Sato, Takashi Suzuki, Hiroyuki Watanabe, Ayumi Kadowaki, Akiyoshi Fukamizu, Peter P Liu, Akinori Kimura, Hiroshi Ito, Josef M Penninger, Yumiko Imai, Keiji Kuba.   

Abstract

Angiotensin converting enzyme 2 (ACE2) is a negative regulator of the renin-angiotensin system (RAS), catalyzing the conversion of Angiotensin II to Angiotensin 1-7. Apelin is a second catalytic substrate for ACE2 and functions as an inotropic and cardioprotective peptide. While an antagonistic relationship between the RAS and apelin has been proposed, such functional interplay remains elusive. Here we found that ACE2 was downregulated in apelin-deficient mice. Pharmacological or genetic inhibition of angiotensin II type 1 receptor (AT1R) rescued the impaired contractility and hypertrophy of apelin mutant mice, which was accompanied by restored ACE2 levels. Importantly, treatment with angiotensin 1-7 rescued hypertrophy and heart dysfunctions of apelin-knockout mice. Moreover, apelin, via activation of its receptor, APJ, increased ACE2 promoter activity in vitro and upregulated ACE2 expression in failing hearts in vivo. Apelin treatment also increased cardiac contractility and ACE2 levels in AT1R-deficient mice. These data demonstrate that ACE2 couples the RAS to the apelin system, adding a conceptual framework for the apelin-ACE2-angiotensin 1-7 axis as a therapeutic target for cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24177423      PMCID: PMC3859384          DOI: 10.1172/JCI69608

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Prolyl endopeptidase purified from granulomatous inflammation in mice.

Authors:  Y Nozaki; N Sato; T Iida; K Hara; K Fukuyama; W L Epstein
Journal:  J Cell Biochem       Date:  1992-07       Impact factor: 4.429

3.  Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Authors:  JiuChang Zhong; Ratnadeep Basu; Danny Guo; Fung L Chow; Simon Byrns; Manfred Schuster; Hans Loibner; Xiu-hua Wang; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circulation       Date:  2010-08-02       Impact factor: 29.690

4.  Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

Authors:  Koichi Yamamoto; Mitsuru Ohishi; Tomohiro Katsuya; Norihisa Ito; Masashi Ikushima; Masaharu Kaibe; Yuji Tatara; Atsushi Shiota; Sumio Sugano; Satoshi Takeda; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

5.  A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.

Authors:  B F O'Dowd; M Heiber; A Chan; H H Heng; L C Tsui; J L Kennedy; X Shi; A Petronis; S R George; T Nguyen
Journal:  Gene       Date:  1993-12-22       Impact factor: 3.688

6.  The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition.

Authors:  K Siddiquee; J Hampton; D McAnally; Lt May; Lh Smith
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

7.  Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells--brief report.

Authors:  Danielle L McLean; Jongmin Kim; Yujung Kang; Hong Shi; G Brandon Atkins; Mukesh K Jain; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

8.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

Authors:  K Tatemoto; M Hosoya; Y Habata; R Fujii; T Kakegawa; M X Zou; Y Kawamata; S Fukusumi; S Hinuma; C Kitada; T Kurokawa; H Onda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

9.  The Xenopus GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis.

Authors:  Y Jiang; T Evans
Journal:  Dev Biol       Date:  1996-03-15       Impact factor: 3.582

10.  ACE2 orthologues in non-mammalian vertebrates (Danio, Gallus, Fugu, Tetraodon and Xenopus).

Authors:  Chih-Fong Chou; Chay Boon Loh; Yik Khoon Foo; Shuo Shen; Burtram C Fielding; Timothy H P Tan; Sehaam Khan; Yue Wang; Seng Gee Lim; Wanjin Hong; Yee-Joo Tan; Jianlin Fu
Journal:  Gene       Date:  2006-04-05       Impact factor: 3.688

View more
  58 in total

Review 1.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

2.  Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.

Authors:  Florence Tatin; Edith Renaud-Gabardos; Anne-Claire Godet; Fransky Hantelys; Francoise Pujol; Florent Morfoisse; Denis Calise; Fanny Viars; Philippe Valet; Bernard Masri; Anne-Catherine Prats; Barbara Garmy-Susini
Journal:  JCI Insight       Date:  2017-06-15

Review 3.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

4.  Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice.

Authors:  Hikari Takeshita; Koichi Yamamoto; Masaki Mogi; Satoko Nozato; Masatsugu Horiuchi; Hiromi Rakugi
Journal:  Hypertens Res       Date:  2019-12-19       Impact factor: 3.872

Review 5.  Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

Authors:  Vaibhav B Patel; Jiu-Chang Zhong; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

Review 6.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

Review 7.  Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin.

Authors:  Carina Ureche; Laura Tapoi; Simona Volovat; Luminita Voroneanu; Mehmet Kanbay; Adrian Covic
Journal:  J Hum Hypertens       Date:  2019-01-18       Impact factor: 3.012

Review 8.  Apelin/APJ system: a promising therapy target for hypertension.

Authors:  Di Wu; Lu He; Linxi Chen
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

9.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

10.  Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis.

Authors:  Keshav K Singh; Gyaneshwer Chaubey; Jake Y Chen; Prashanth Suravajhala
Journal:  Am J Physiol Cell Physiol       Date:  2020-06-08       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.